Doxorubicin (D), gemcitabine (G), ifosfamide (I) and the EZH2 inhibitor EPZ-011989 in epithelioid sarcoma (ES): A comparison of different regimens in a patient-derived xenograft (PDX) model.

11578 Background: ES is a rare soft tissue sarcoma with two variants, i.e., the proximal and the distal. Retrospective data on the activity of anthracycline- and G-based regimens are available. EZH2 inhibitors, which target the INI1 pathway that is inactivated in ES, are currently being tested in clinical trial. Comparisons of these agents are not available and unlikely to be prospectively evaluated. We comparatively assess these agents in a...